 WALTHAM, Mass.--BUSINESS WIRE--Deciphera Pharmaceuticals, Inc. NASDAQ:DCPH today announced financial results for the first quarter ended March 31, 2021, and provided a corporate update. We are excited by the continuing successful commercial launch of QINLOCK in the U.S. as we solidify its position among GIST prescribers and patients and expand access to this important medicine globally. We also remain focused on realizing QINLOCKs potential in earlier lines of therapy, said Steve Hoerter 